- Home
- CRNC vs RIGL Comparison
CRNC vs RIGL Comparison
Compare CRNC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNC
- RIGL
- Stock Information
- Founded
- CRNC 2020
- RIGL 1996
- Country
- CRNC United States
- RIGL United States
- Employees
- CRNC N/A
- RIGL N/A
- Industry
- CRNC EDP Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CRNC Technology
- RIGL Health Care
- Exchange
- CRNC Nasdaq
- RIGL Nasdaq
- Market Cap
- CRNC 418.7M
- RIGL 335.5M
- IPO Year
- CRNC N/A
- RIGL 2000
- Fundamental
- Price
- CRNC $9.63
- RIGL $18.62
- Analyst Decision
- CRNC Buy
- RIGL Buy
- Analyst Count
- CRNC 7
- RIGL 5
- Target Price
- CRNC $9.43
- RIGL $36.40
- AVG Volume (30 Days)
- CRNC 1.9M
- RIGL 192.9K
- Earning Date
- CRNC 08-07-2025
- RIGL 08-05-2025
- Dividend Yield
- CRNC N/A
- RIGL N/A
- EPS Growth
- CRNC N/A
- RIGL N/A
- EPS
- CRNC N/A
- RIGL 2.08
- Revenue
- CRNC $254,250,000.00
- RIGL $203,077,000.00
- Revenue This Year
- CRNC N/A
- RIGL $14.41
- Revenue Next Year
- CRNC $8.02
- RIGL $15.97
- P/E Ratio
- CRNC N/A
- RIGL $9.02
- Revenue Growth
- CRNC N/A
- RIGL 70.16
- 52 Week Low
- CRNC $2.34
- RIGL $7.48
- 52 Week High
- CRNC $27.50
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- CRNC 55.57
- RIGL 39.75
- Support Level
- CRNC $8.07
- RIGL $18.14
- Resistance Level
- CRNC $10.23
- RIGL $19.21
- Average True Range (ATR)
- CRNC 0.70
- RIGL 0.84
- MACD
- CRNC 0.06
- RIGL -0.28
- Stochastic Oscillator
- CRNC 61.48
- RIGL 10.89
About CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.